Literature DB >> 26885235

Expressions and clinical significance of factors related to giant cell tumor of bone.

Chong Li1, Xiaojuan Zheng2, Michelle Ghert3, Hai Li2, Bin Wang4, Yizhong Feng5.   

Abstract

BACKGROUND: Giant cell tumor of bone (GCTB) is a relatively rare tumor of bone, characterized by numerous multinucleated cells, severe osteolysis, and local recurrence.
PURPOSE: To explore the role of S-phase kinase-interacting protein 2 (Skp2), cyclin-dependent kinase inhibitor p27, and the transcription factor E2F-1 expression in the development of GCTB, and the relationship of expression of these proteins with tumor recurrence.
METHODS: Forty-four patients with GCTB were selected and demographic and clinical data were collected. The levels of Skp2, p27, and E2F-1 protein expression were immunohistochemically assessed in surgical specimens.
RESULTS: Skp2, p27, and E2F-1 proteins were detected in the nuclei of mononuclear stromal cells. Positive Skp2 expression was observed in 66% (29/44) of GCTB patient samples, and positive p27 expression was found in 39% (17/44) of samples. Within almost all GCTB patients, there was an inverse correlation between Skp2- and p27-positive tumor cells. Positive expression of E2F-1 was present in 28 of 44 (64%) patients. In addition, expression of skp2 and p27, infiltration of soft tissues, and surgical operation were significantly associated with recurrence in patients with GCTB.
CONCLUSION: The immunohistochemical assessment of Skp2, p27 and E2F-1 may be useful in the diagnosis of GCTB and prediction of its prognosis.

Entities:  

Keywords:  E2F-1; GCTB; Skp2; expression; p27; recurrence

Year:  2015        PMID: 26885235      PMCID: PMC4730021     

Source DB:  PubMed          Journal:  Int J Clin Exp Med        ISSN: 1940-5901


  25 in total

1.  SKP2 is required for ubiquitin-mediated degradation of the CDK inhibitor p27.

Authors:  A C Carrano; E Eytan; A Hershko; M Pagano
Journal:  Nat Cell Biol       Date:  1999-08       Impact factor: 28.824

Review 2.  The ubiquitin-proteasome pathway: on protein death and cell life.

Authors:  A Ciechanover
Journal:  EMBO J       Date:  1998-12-15       Impact factor: 11.598

3.  Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas.

Authors:  M Loda; B Cukor; S W Tam; P Lavin; M Fiorentino; G F Draetta; J M Jessup; M Pagano
Journal:  Nat Med       Date:  1997-02       Impact factor: 53.440

4.  Skp2 is oncogenic and overexpressed in human cancers.

Authors:  M Gstaiger; R Jordan; M Lim; C Catzavelos; J Mestan; J Slingerland; W Krek
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

5.  Prognostic value of p27(Kip1) and CyclinD1 expression in esophageal cancer.

Authors:  A Itami; Y Shimada; G Watanabe; M Imamura
Journal:  Oncology       Date:  1999-11       Impact factor: 2.935

6.  Targeted disruption of Skp2 results in accumulation of cyclin E and p27(Kip1), polyploidy and centrosome overduplication.

Authors:  K Nakayama; H Nagahama; Y A Minamishima; M Matsumoto; I Nakamichi; K Kitagawa; M Shirane; R Tsunematsu; T Tsukiyama; N Ishida; M Kitagawa; K Nakayama; S Hatakeyama
Journal:  EMBO J       Date:  2000-05-02       Impact factor: 11.598

7.  Inverse relation between levels of p27(Kip1) and of its ubiquitin ligase subunit Skp2 in colorectal carcinomas.

Authors:  D Hershko; G Bornstein; O Ben-Izhak; A Carrano; M Pagano; M M Krausz; A Hershko
Journal:  Cancer       Date:  2001-05-01       Impact factor: 6.860

8.  Prognostic role of the cyclin-dependent kinase inhibitor p27 in non-small cell lung cancer.

Authors:  V Esposito; A Baldi; A De Luca; A M Groger; M Loda; G G Giordano; M Caputi; F Baldi; M Pagano; A Giordano
Journal:  Cancer Res       Date:  1997-08-15       Impact factor: 12.701

9.  Giant-cell tumor of bone.

Authors:  M Campanacci; N Baldini; S Boriani; A Sudanese
Journal:  J Bone Joint Surg Am       Date:  1987-01       Impact factor: 5.284

10.  Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27.

Authors:  M Pagano; S W Tam; A M Theodoras; P Beer-Romero; G Del Sal; V Chau; P R Yew; G F Draetta; M Rolfe
Journal:  Science       Date:  1995-08-04       Impact factor: 47.728

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.